Optimizing treatment for platinum‐resistant ovarian clear cell carcinoma: Efficacy of gemcitabine and combination therapy with bevacizumab
Collectively, the current findings suggest that GEM, particularly as a first-line treatment, may improve the prognosis of patients with PR-OCCC. Moreover, Bev combination therapy is a promising option for treating PR-OCCC.
Authors
- Yasuyuki Hirashima (ORCID: https://orcid.org/0000-0003-0269-9313)
- Nao Kino (ORCID: https://orcid.org/0000-0001-8570-8152)
- Ayumi Taguchi (ORCID: https://orcid.org/0000-0002-5491-3871)
- Saki Tsuchimochi
- Akiko Furusawa (ORCID: https://orcid.org/0000-0003-1279-4971)
- Masako Ikemura (ORCID: https://orcid.org/0000-0002-7148-778X)
- Hideo Arai (ORCID: https://orcid.org/0000-0001-6013-894X)
- Kenbun Sone
- Katsuhiko Nara
- Aya Ishizaka (ORCID: https://orcid.org/0000-0003-2800-2430)
- Yasunori Yoshino (ORCID: https://orcid.org/0000-0001-8861-9753)
- Harunori Honjoh (ORCID: https://orcid.org/0009-0004-3953-6010)
- Naoyuki Miyasaka (ORCID: https://orcid.org/0000-0002-4713-8352)
- Tsubasa Hiraki
Institutions
- Tokyo Metropolitan Komagome Hospital (JP)
- Shizuoka Cancer Center (JP)
- University of Tokyo Hospital (JP)
- Institute of Science Tokyo (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Cancer
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1002/cncr.70071
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Japan Society for the Promotion of Science